Rainsure Digital PCR: Ultra-Sensitive MRD Detection for Liquid Biopsy and BCR-ABL MR 5.0 Monitoring

Rainsure Digital PCR: Precision MRD Detection with Unmatched Sensitivity

Minimal Residual Disease (MRD) detection plays a critical role in monitoring cancer recurrence, especially in hematological malignancies like leukemia. Rainsure Digital PCR (dPCR) offers an industry-leading solution for MRD tracking—delivering ultra-sensitive, quantitative detection directly from liquid biopsy samples with accuracy that outperforms both NGS and qPCR.

With detection limits as low as 0.001% (1 in 100,000), and MR 5.0 sensitivity for BCR-ABL p210, Rainsure is redefining how clinicians monitor patient response, guide therapy decisions, and detect relapse earlier than ever before.

Key Benefits of Rainsure Digital PCR in MRD Applications

Sensitivity Down to 0.001%

Track MRD at levels as low as 1 in 100,000 cells—crucial for early relapse prediction and long-term remission assessment.

Liquid Biopsy Ready

Rainsure is optimized for cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) in blood, enabling non-invasive monitoring.

MR 5.0 Sensitivity in BCR-ABL (p210)

Detect and quantify BCR-ABL1 fusion transcripts at MR 5.0, meeting the highest clinical standards for chronic myeloid leukemia (CML) monitoring.

Reports in Both IS and MR Values

Rainsure provides International Scale (IS) and MR (Molecular Response) value reporting, making it fully compatible with global clinical guidelines.

 Superior to qPCR and NGS

· Faster turnaround and fewer steps than NGS

· Greater precision and reproducibility than qPCR

· No need for reference standards or calibration curves

Clinical Applications for MRD with Rainsure Digital PCR

Chronic Myeloid Leukemia (CML)

· Quantitative monitoring of BCR-ABL1 transcripts

· Achieve and track deep molecular responses (MR4.5, MR5.0)

· Enable early treatment adaptation based on IS levels

Acute Lymphoblastic Leukemia (ALL)

· Detect MRD in bone marrow and plasma

· Identify relapse risk post-therapy

· Guide timing of hematopoietic stem cell transplant (HSCT)

 Solid Tumors via Liquid Biopsy

· Monitor ctDNA mutations from breast, lung, or colorectal cancers

· Detect molecular relapse before clinical symptoms

· Track efficacy of targeted therapies over time

Rainsure dPCR vs NGS and qPCR

Frequently Asked Questions (FAQs)

 Can Rainsure detect MRD earlier than NGS?

Yes. Rainsure dPCR achieves higher sensitivity and faster results than NGS, making it ideal for early relapse detection and routine clinical monitoring.

What does MR5.0 mean in leukemia?

MR5.0 indicates a 5-log reduction in BCR-ABL1 transcript levels, corresponding to a residual disease level of 0.001%. Rainsure fully supports MR4.0 to MR5.0 reporting.

Is it compatible with existing IS standards?

Yes. Rainsure reports results on the International Scale (IS), ensuring global consistency in CML management.

Conclusion

Rainsure Digital PCR delivers unrivaled MRD detection sensitivity, precise BCR-ABL monitoring to MR5.0, and full IS/MR value reporting—surpassing the capabilities of NGS and qPCR. Combined with its compatibility with liquid biopsy, Rainsure provides clinicians with a powerful tool for early intervention, treatment guidance, and improved patient outcomes in leukemia and beyond.

Stay one step ahead of relapse. Choose Rainsure Digital PCR for MRD precision that saves lives.